The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Brand Name :
Krazati
Synonyms :
adagrasib
Class :
Antineoplastics, KRAS Inhibitors
Dosage forms & Strengths:Â
Adult:Â
TabletÂ
200 mgÂ
600
mg
Orally
twice a day
Continue until the illness progresses or intolerable toxicity occurs.
Safety and efficacy are not seen in pediatricsÂ
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may increase the level of serum concentration of adagrasib
may enhance the concentration of serum when combined with adagrasib
may increase the serum concentration of each other when combined
adagrasib: they may increase the QTc-prolonging effect of clozapine
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
acetaminophen and phenyltoloxamine
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhace the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the serum concentration of each other when it is combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may increase the QTc prolonging effect
may increase the serum concentration of CYP2C9 Substrates
may decrease the therapeutic effect when combined with lenograstim
may decrease the therapeutic effect when combined with lipegfilgrastim
may have an increasingly adverse effect when combined with antineoplastic agents
may enhance the concentration of serum when combined with adagrasib
may increase the QTc-prolonging effect of QT-prolonging CYP3A4 Inhibitors
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
abiraterone acetate and niraparibÂ
may decrease the therapeutic effect of Immunosuppressants
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
it may enhance the qtc interval when combined with lofexidine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may enhance the severity of adverse effects when combined
may enhance the severity of adverse effects when combined
may decrease the serum concentration of CYP3A4 Inducers
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
may diminish the anti-neoplastic activity of corticosteroids
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
ximelagatran (investigational)Â
The combination of adagrasib may lead to a reduced metabolism of ximelagatran
Combining levobetaxolol and adagrasib can diminish levobetaxolol’s metabolism
When adagrasib and levobupivacaine are combined, the risk or seriousness of methemoglobinemia could rise
When domeperidone and adagrasib is used together, this leads to reduction in the domeperidone’s metabolism
When adagrasib is used together with fluconazole, this leads to reduction in the adagrasib metabolism
When acetohexamide is used together with adagrasib, this lead to reduction in acetohexamide’s metabolism
When adagrasib is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When adagrasib is used together with elbasvir, this leads to a rise in the concentration serum of elbasvir
When adagrasib is used together with grazoprevir, this leads to a rise in the concentration serum of grazoprevir
When ponesimod is used together with adagrasib, this leads to enhanced risk or seriousness of bradycardia
may decrease the therapeutic effect of immunosuppressive Agents
measles, mumps, rubella, and varicella vaccine, live 
may decrease the therapeutic effect of immunosuppressive Agents
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressive Agents
may decrease the therapeutic effect of immunosuppressive Agents
smallpox (vaccinia) vaccine, live
may decrease the therapeutic effect of immunosuppressive Agents
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
may enhance the severity of gastrointestinal bleeding when combined
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
monitor for serum concentration of clonidine, which is increased when adagrasib is used in combination
the rate of metabolism of adagrasib may be reduced
the risk of methemoglobinemia may be increased
the rate of metabolism of candesartan cilexetil may be reduced
the metabolism of oxycodone can be decreased when combined with adagrasib
When adagrasib is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
When adagrasib is used together with lomitapide, this leads to enhanced concentration serum of lomitapide
>10%:Â
Diarrhea Â
NauseaÂ
Decreased lymphocytes Â
FatigueÂ
Vomiting Â
Increased ASTÂ Â
Decreased sodium Â
Decreased hemoglobin Â
Increased creatinine Â
Decreased albumin Â
Increased ALTÂ Â
Pneumonia Â
Dizziness Â
Constipation Â
Abdominal pain Â
1-10%:Â
Hepatoxicity Â
Dyspnea Â
Decreased hemoglobin Â
Decreased sodium Â
Fatigue Â
Musculoskeletal pain Â
Renal impairment Â
Prolonged QTÂ Â
Increased ASTÂ Â
Increased ALTÂ Â
Nausea Â
Decreased appetite Â
Decreased potassium Â
Increased lipaseÂ
<1%:Â
DiarrheaÂ
VomitingÂ
DizzinessÂ
CoughÂ
Decreased albuminÂ
Adagrasib is contraindicated in patients hypersensitive to the active ingredient.Â
Pregnancy consideration:Â Â
No data is available regarding the use of the drug in the pregnant females.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of the drug in breast milk.Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: adagrasibÂ
Pronounced: ada-gras-ibÂ
Why do we use adagrasib?Â
Adagrasib is an antineoplastic agent. It is used to treat non-small lung cancer.